These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
622 related articles for article (PubMed ID: 24983194)
1. [New treatment options for metastatic melanoma]. Tietze JK; Berking C Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194 [No Abstract] [Full Text] [Related]
2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
3. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. Akabane H; Sullivan RJ Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880 [TBL] [Abstract][Full Text] [Related]
4. The future of melanoma therapy: developing new drugs and improving the use of old ones. Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206 [No Abstract] [Full Text] [Related]
5. Strides in melanoma announced: maximizing value comes next. Tuma RS J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727 [No Abstract] [Full Text] [Related]
6. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue". Jarkowski A; Norris L; Trinh VA Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920 [TBL] [Abstract][Full Text] [Related]
7. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
9. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D; Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153 [TBL] [Abstract][Full Text] [Related]